

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.		FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/890,997		10/02/2001	Martin Friede	B 45181	1794
20462	7590	10/03/2003		EXAMINER	
		ECHAM CORP	ANGELL, JON E		
CORPORATE INTELLECTUAL PROPERTY-US, UW2220 P. O. BOX 1539				ART UNIT	PAPER NUMBER
KING OF I	PRUSSIA	, PA 19406-0939	1635		
				DATE MAILED: 10/03/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/890,997	FRIEDE ET AL.				
Office Action Summary	Examiner	Art Unit				
	J. Eric Angell	1635				
Th MAILING DATE of this communication appears on the cover she t with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on						
, _	s action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4)⊠ Claim(s) 30-69 is/are pending in the application	n.					
,	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.	m mom concideration.					
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) <u>30-69</u> are subject to restriction and/or	election requirement					
Application Papers	olosion roquii omomi.					
9) The specification is objected to by the Examiner						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the	drawing(s) be held in abeyance. Se	ee 37 CFR 1.85(a).				
11)☐ The proposed drawing correction filed on	is: a) ☐ approved b) ☐ disappro	ved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.						
12)☐ The oath or declaration is objected to by the Exa	aminer.					
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents	have been received.					
2. Certified copies of the priority documents	have been received in Application	on No				
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) The translation of the foreign language provisional application has been received.						
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)	A) [] Interview Outcome	(DTO 442) Bonor No(a)				
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)				

Art Unit: 1635

DETAILED ACTION

Claims 1-29 have been cancelled and new claims 30-69 have been added. Claims 30-69 are currently pending in the application and are addressed herein.

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 30-59, drawn to an immunogenic composition.

Group II, claim(s) 60, drawn to a delivery device.

Group III, claim(s) 61, drawn to a method for inducing an immune response.

Group IV, claim(s) 62 and 64, drawn to method of treatment.

Group V, claim(s) 63 and 65, drawn to method of preventing a disease.

Group VI, claim(s) 66, drawn to a method for inducing a systemic antigen-specific response.

Group VII, claim(s) 67, drawn to method of making an immunogenic composition (using liposome).

Group VIII, claim(s) 68 and 69, drawn to a method of making an immunogenic composition (using oil in water emulsion).

2. The inventions listed as Groups I-VIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: in order for a technical feature to be considered a special technical feature it must be novel. In the instant case the immunogenic composition of claim 30 links all of the inventions. However, this composition is not novel, as evidenced by

Art Unit: 1635

WO 98/56415 A (AQUILA...), which was sited as an "X" reference in the international search report. Therefore, there is no special technical feature linking the claims.

3. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species of antigens are as follows (see claims 56-57):

- 1) MAGE
- 2) BAGE
- 3) CAGE
- 4) MUC-1
- 5) Her-2neu
- 6) LnRH
- 7) CEA
- 8) PSA
- 9) KSA (GA733)
- 10) PRAME

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

The following claim(s) are generic: 30-65.

Application/Control Number: 09/890,997

Art Unit: 1635

4. The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: in order for a technical feature to be special it must be novel. However, in the instant case, the species of antigens are not novel (for instance Her-2neu is a well known antigen). Therefore, there is no special technical feature linking the species.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to J. Eric Angell whose telephone number is (703) 605-1165. The examiner can normally be reached on M-F (8:00-4:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John L. LeGuyader can be reached on (703) 308-0447. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Application/Control Number: 09/890,997

Art Unit: 1635

Page 5

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

J. Eric Angell Art Unit 1635 DAVET. NGUYEN PRIMARY EXAMINED